AstraZeneca investors push back on $400bn Bristol Myers Squibb tie-up
A potential $400 billion combination between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) is meeting organized resistance from AstraZeneca's own shareholders before any definitive agreement has been filed. Investors…